GTBP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.5M
+58.4%
2.8M
-49.1%
5.6M
+65.4%
3.4M
+123.5%
1.5M
R&D
1.1M
+155.4%
413.0K
-70.0%
1.4M
+117.0%
634.0K
+74.7%
363.0K
SG&A
3.5M
+42.0%
2.4M
-42.3%
4.2M
+53.5%
2.7M
+139.0%
1.1M
Operating Income
-4512000
-58.4%
-2848000
+49.1%
-5595000
-65.4%
-3382000
-123.5%
-1513000
EBITDA
-4512000
-58.4%
-2848000
+49.1%
-5595000
-65.4%
-3382000
-123.5%
-1513000
Net Income
-4518000
-59.5%
-2833000
+87.7%
-23031000
-377.5%
8.3M
+127.5%
-30169000
EPS (Basic)
$-3.00
-9.1%
$-2.75
-10.0%
$-2.50
-109.6%
$26.00
+109.5%
$-273.00
EPS (Diluted)
$-3.00
-9.1%
$-2.75
-10.0%
$-2.50
-109.6%
$26.00
+109.5%
$-273.00
Shares (Diluted)
1.6M
+28.2%
1.2M
-89.5%
11.6M
+7240.4%
157.6K
+42.2%
110.9K
GT Biopharma (GTBP) โ€” Financials